| 1 | Orkambi | Vertex Pharmaceuticals Inc | lumacaftor 200 mg/ivacaftor 125 mg | $5,000 | $4,219 | 07-Feb-15 | To treat cystic fibrosis | Drug Trials Snapshot | First-in-Class, Rare Diseases, Fast Track, Breakthrough, Priority Review, FDA used expedited development and review methods | Yes | Chemical |
| 2 | Darzalex | Janssen Biotech | daratumumab | $4,000 | $1,407 | 16-Nov-15 | To treat patients with multiple myeloma who have received at least three prior treatments. | Drug Trial Snapshot | First-in-Class, Rare Diseases, Fast Track, Breakthrough, Priority Review, Accelerated Approval, FDA used expedited development and review methods | Yes | Biological |
| 3 | Entresto | Novartis Pharma | sacubitril/valsartan | $3,730 | $4,000 | 07-Jul-15 | To treat heart failure | Drug Trials Snapshot | First-in-Class, Fast Track, Priority Review, FDA used expedited development and review methods | Yes | Chemical |
| 4 | Ibrance | Pfizer, Inc. | palbociclib | $3000 to $5000 | $4,214 | 02-Mar-15 | To treat advanced (metastatic) breast cancer | Drug Trials Snapshot | First-in-Class, Breakthrough, Priority Review, Accelerated Approval, FDA used expedited development and review methods | Yes | Chemical |
| 5 | Tagrisso | Astra Zeneca Pharmaceuticals | osimertinib | $3,000 | $1,078 | 13-Nov-15 | To treat certain patients with non-small cell lung cancer | Drug Trials Snapshot | Rare Diseases, Fast Track, Breakthrough, Priority Review, Accelerated Approval, FDA used expedited development and review methods | Yes | Chemical |
| 6 | Tresiba | Novo Nordisk | insulin degludec injection | $3,000 | N/A | 25-Sep-15 | To improve blood sugar (glucose) control in adults with diabetes mellitus | Drug Trials Snapshot | | No | Chemical |
| 7 | Repatha | Amgen Inc. | evolocumab | $3,000 | $2,042 | 27-Aug-15 | To treat certain patients with high cholesterol | Drug Trials Snapshot | Rare Diseases | No | Biological |
| 8 | Praluent | Sanofi-Aventis U.S. | alirocumab | $3,000 | $1,980 | 24-Jul-15 | To treat certain patients with high cholesterol | Drug Trials Snapshot | First-in-Class | Yes | Biological |
| 9 | Cosentyx | Novartis Pharmaceuticals Corporation. | secukinumab | $1,800 | $1,819 | 21-Jan-15 | To treat adults with moderate-to-severe plaque psoriasis | Drug Trials Snapshot | First-in-Class | No | Biological |
| 10 | Ninlaro | Takeda Pharmaceuticals | ixazomib | $1,500 | $1,241 | 20-Nov-15 | To treat people with multiple myeloma who have received at least one prior therapy | Drug Trials Snapshot | Rare Diseases, Priority Review, FDA used expedited development and review methods | Yes | Chemical |
| 11 | Uptravi | Actelion Pharmaceuticals US, Inc. | selexipag | $1,400 | $941 | 22-Dec-15 | To treat pulmonary arterial hypertension | Drug Trial Snapshot | Rare Diseases | Yes | Chemical |
| 12 | Rexulti | Otsuka Pharmaceutical Company Ltd | brexpiprazole | $1,400 | $922 | 07-Oct-15 | To treat schizophrenia and as an add on to an antidepressant to treat major depressive disorder | Drug Trials Snapshot (treatment of major depressive disorder), Drug Trials Snapshot (treatment of schizophrenia) | | Yes | Chemical |
| 13 | Veltassa | Relypsa Inc. | patiromer for oral suspension | $1,000 | N/A | 21-Oct-15 | To treat hyperkalemia, a serious condition in which the amount of potassium in the blood is too high. | Drug Trials Snapshot | | Yes | Chemical |
| 14 | Avycaz | Forest Laboratories, Inc. | ceftazidime-avibactam | $1,000 | N/A | 25-Feb-15 | To treat adults with complicated intra-abdominal infections (cIAI), in combination with metronidazole, and complicated urinary tract infections (cUTI), including kidney infections (pyelonephritis), who have limited or no alternative treatment options. | Drug Trials Snaphot (cIAI), Drug Trials Snapshot (cUTI) | Fast Track, Priority Review, FDA used expedited development and review methods, Qualified Infectious Disease Program Designations | Yes | Chemical |
| 15 | Kanuma | Alexion Pharmaceuticals Inc | sebelipase alfa | $800 to $1500 | $538 | 12-Aug-15 | To treat patients with a rare disease known as lysosomal acid lipase (LAL) deficiency | | First-in-Class, Rare Diseases, Fast Track, Breakthrough, Priority Review, FDA used expedited development and review methods | No | Biological |
| 16 | Cotellic | Genentech | cobimetinib | $800 | $281 | 11-Oct-15 | To be used in combination with vemurafenib to treat advanced melanoma that has spread to other parts of the body or can’t be removed by surgery, and that has a certain type of abnormal gene (BRAF V600E or V600K mutation) | Drug Trials Snapshot | Rare Diseases, Fast Track, Priority Review, FDA used expedited development and review methods | No | Chemical |
| 17 | Odomzo | Novartis Pharmaceuticals Corporation | sonidegib | $800 | $190 | 24-Jul-15 | To treat patients with locally advanced basal cell carcinoma that has recurred following surgery or radiation therapy, or who are not candidates for surgery or radiation therapy. | Drug Trials Snapshot | | No | Chemical |
| 18 | Nucala | GlaxoSmithKline | mepolizumab | $600 to $1000 | £500 | 11-Apr-15 | For use with other asthma medicines for the maintenance treatment of asthma in patients age 12 years and older. | | First-in-Class | Yes | Biological |
| 19 | Aristada | Alkermes, Inc | aripiprazole lauroxil | $550 | $362 | 10-Jun-15 | To treat adults with schizophrenia | Drug Trials Snapshot | | Yes | Chemical |
| 20 | Zurampic | Ardea Biosciences INC. | lesinurad | $500 | $380 | 22-Dec-15 | To treat high blood uric acid levels associated with gout | | | Yes | Chemical |
| 21 | Strensiq | Alexion Pharmaceuticals Inc. | asfotase alfa | $500 | $352 | 23-Oct-15 | To treat perinatal, infantile and juvenile-onset hypophosphatasia (HPP). | Drug Trials Snapshot | First-in-Class, Rare Diseases, Fast Track, Breakthrough, Priority Review, FDA used expedited development and review methods | No | Biological |
| 22 | Cresemba capsule injection | Astellas Pharma US, Inc. | isavuconazonium sulfate | $500 | $72 | 03-Jun-15 | To treat adults with invasive aspergillosis and invasive mucormycosis, rare but serious infections | Drug Trials Snapshot (aspergillosis), Drug Trials Snapshot (mucormycosis) | Rare Diseases, Priority Review, FDA used expedited development and review methods, Qualified Infectious Disease Program Designations | Yes | Chemical |
| 23 | Natpara | NPS Pharmaceuticals, Inc. | parathyroid horomone | $500 | $568 | 23-Jan-15 | To control hypocalcemia (low blood calcium levels) in patients with hypoparathyroidism | Drug Trials Snapshot | Rare Diseases | Yes | Biological |
| 24 | Portrazza | Eli Lilly and Company | necitumumab | $450 | $551 | 24-Nov-15 | To treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) who have not previously received medication specifically for treating their advanced lung cancer | Drug Trial Snapshot | Rare Diseases, Fast Track, FDA used expedited development and review methods | Yes | Biological |
| 25 | Kengreal | The Medicines Company | canegrelor | $440 | $95 | 22-Jun-15 | To prevent the formation of harmful blood clots in the coronary arteries for adult patients undergoing percutaneous coronary intervention | Drug Trials Snapshot | | No | Chemical |
| 26 | Viberzi | Forest Pharmaceuticals, Inc | eluxadoline | $440 | N/A | 27-May-15 | To treat irritable bowel syndrome with diarrhea (IBS-D) in adult men and women. | Drug Trials Snapshot | Fast Track, Priority Review, FDA used expedited development and review methods | Yes | Chemical |
| 27 | Lenvima | Eisai Inc | lenvatinib | $424 | $728 | 13-Feb-15 | To treat patients with progressive, differentiated thyroid cancer (DTC) whose disease progressed despite receiving radioactive iodine therapy (radioactive iodine refractory disease). | Drug Trials Snapshot | Rare Diseases, Priority Review, FDA used expedited development and review methods | Yes | Chemical |
| 28 | Varubi | Tesaro Inc. | rolapitant | $400 | N/A | 9-Feb-15 | To prevent delayed phase chemotherapy-induced nausea and vomiting (emesis) | Drug Trials Snapshot | | Yes | Chemical |
| 29 | Yondelis | Janssen | trabectedin | $330 | N/A | 23-Oct-15 | To treat specific soft tissue sarcomas (STS) – liposarcoma and leiomyosarcoma – that cannot be removed by surgery (unresectable) or is advanced (metastatic). | Drug Trials Snapshot | Rare Diseases, Priority Review, FDA used expedited development and review methods | No | Chemical |
| 30 | Corlanor | Amgen Inc | ivabradine | $300 to $1000 | $300 | 15-Apr-15 | To reduce hospitalization from worsening heart failure. | Drug Trials Snapshot | First-in-Class, Fast Track, Priority Review, FDA used expedited development and review methods | No | Chemical |
| 31 | Empliciti | Bristol-Myers Squibb | elotuzumab | $300 | $679 | 30-Nov-15 | To treat people with multiple myeloma who have received one to three prior medications | Drug Trials Snapshot | First-in-Class, Rare Diseases, Breakthrough, Priority Review, FDA used expedited development and review methods | Yes | Biological |
| 32 | Kybella | Kythera Biopharmaceuticals Inc. | deoxycholic acid | $300 | $408 | 29-Apr-15 | To treat adults with moderate-to-severe fat below the chin, known as submental fat | Drug Trials Snapshot | | Yes | Chemical |
| 33 | Bridion | Merck Sharp and Dohme Corp. | sugammadex | $270 | $702 | 15-Dec-15 | To reverse effects of neuromuscular blocking drugs used during surgery | Drug Trials Snapshot | First-in-Class, Priority Review, FDA used expedited development and review methods | No | Chemical |
| 34 | Farydak | Novartis Pharmaceuticals. | panobinostat | $250 | N/A | 23-Feb-15 | To treat patients with multiple myeloma | Drug Trials Snapshot | Rare Diseases, Priority Review, Accelerated Approval, FDA used expedited development and review methods | Yes | Chemical |
| 35 | Savaysa | Daiichi Sankyo | edoxaban | $220 | $592 | 8-Jan-15 | To reduce the risk of stroke and dangerous blood clots (systemic embolism) in patients with atrial fibrillation that is not caused by a heart valve problem | Drug Trials Snapshot (atrial fibrillation), Drug Trials Snapshot (venous thromboembolism) | | No | Chemical |
| 36 | Vraylar | Forest Laboratories LLC | cariprazine | $200 to $300 | N/A | 17-Sep-15 | To treat schizophrenia and bipolar disorder in adults | Drug Trials Snapshot | | Yes | Chemical |
| 37 | Addyi | Sprout Pharmaceuticals | flibanserin | $100 to $300 | N/A | 18-Aug-15 | To treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women | Drug Trials Snapshot | First-in-Class | Yes | Chemical |
| 38 | Unituxin | United Therapeutics | dinutuximab | $60 to $150 | $85 | 03-Oct-15 | To treat pediatric patients with high-risk neuroblastoma | Drug Trials Snapshot | First-in-Class, Rare Diseases, Priority Review, FDA used expedited development and review methods | Yes | Biological |
| 39 | Genvoya | Gilead Sciences Inc. | a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine and $4,223 | 11-May-15 | For use as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older | Drug Trials Snapshot | Fast Track, FDA used expedited development and review methods | Yes | Chemical |
| 40 | Alecensa | Genentech | alectinib | N/A | $317 | 12-Nov-15 | To treat ALK-positive lung cancer | Drug Trial Snapshot | Rare Diseases, Breakthrough, Priority Review, Accelerated Approval, FDA used expedited development and review methods | No | Chemical |
| 41 | Praxbind | Boehringer Ingelheim | idarucizumab | N/A | N/A | 16-Oct-15 | For use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency situations when there is a need to reverse Pradaxa’s blood-thinning effects. | Drug Trials Snapshot | First-in-Class, Rare Diseases, Breakthrough, Priority Review, Accelerated Approval, FDA used expedited development and review methods | Yes | Biological |
| 42 | Lonsurf | Taiho Oncology Inc | trifluridine and tipiracil | N/A | $184 | 22-Sep-15 | To treat patients with an advanced form of colorectal cancer who are no longer responding to other therapies | Drug Trials Snapshot | Fast Track, FDA used expedited development and review methods | No | Chemical |
| 43 | Xuriden | Wellstat Therapeutics Corporation | uridine triacetate | N/A | N/A | 9-Apr-15 | To treat patients with hereditary orotic aciduria | Drug Trials Snapshot | First-in-Class, Rare Diseases, Breakthrough, Priority Review, FDA used expedited development and review methods | Yes | Chemical |
| 44 | Daklinza | Bristol-Myers Squibb | daclatasvir | N/A | N/A | 24-Jul-15 | To treat chronic hepatitis C virus (HCV) genotype 3 infections | Drug Trials Snapshot | Fast Track, Priority Review, FDA used expedited development and review methods | No | Chemical |
| 45 | Cholbam | Asklepion Pharmaceuticals LLC. | cholic acid | N/A | N/A | 17-Mar-15 | To treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for patients with peroxisomal disorders | Drug Trials Snapshot (bile acid synthesis disorders), Drug Trials Snapshot (peroxisomal disorders) | Rare Diseases, Priority Review, FDA used expedited development and review methods | No | Chemical |
